Media December 10, 2024: France’s MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD – a formal study will read out early next year – Biotech TV MaaT PharmaDecember 11, 2024
Media December 5, 2024: The Quest to Turn Human Waste Into Medicine – Bloomberg MaaT PharmaDecember 6, 2024
Media October 25, 2024: Le Journal des biotechs : Hervé Affagard, MaaT Pharma (French only) MaaT PharmaOctober 29, 2024
Media January 21, 2024: Le microbiote à l’attaque du cancer – Les Echos Investir (French only) MaaT PharmaJanuary 22, 2024
Media December 21, 2023: MaaT Pharma et Skyepharma mettent en service leur usine de médicaments à base de microbiote – Les Echos (French only) MaaT PharmaJanuary 22, 2024
Media December 18, 2023: Microbiome-based treatment shows potential in graft-versus-host disease – BioPharma reporter MaaT PharmaJanuary 22, 2024
Media December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease – EPR MaaT PharmaJanuary 22, 2024
Media December 11, 2023: MaaT Pharma : dans la maladie aigüe du greffon contre l’hôte, MaaT Pharma annonce des résultats prometteurs – BFM Bourse (French only) MaaT PharmaJanuary 22, 2024
Media December 5, 2023: En Isère, au cœur du nouveau site de MaaT Pharma pour produire son traitement microbiote – L’Usine Nouvelle (French only) MaaT PharmaJanuary 22, 2024
Media November 28, 2023: “Microbiote tous en selles !” – France Culture (French only) MaaT PharmaJanuary 22, 2024
